BM
BMY.US Bristol-Myers Squibb Company
- Market cap
- USD 130B
- P/E
- 14.1x
- P/B
- 5.44x
- ROE
- 46.5%
- Dividend yield
- 3.89%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BMY.US undervalued?
Graham numberBMY.US trades 84.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bristol-Myers Squibb Company fundamental analysis
No fundamental analysis for Bristol-Myers Squibb Company yet.
Bristol-Myers Squibb Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresecta…
Full company profileBristol-Myers Squibb Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bristol-Myers Squibb Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.4B | 20.8B | 22.6B | 26.1B | 42.5B | 46.4B | 46.2B | 45.0B | 48.3B | 48.2B | 50.0B |
| Gross Profit | 14.5B | 14.8B | 16.1B | 18.1B | 30.7B | 36.4B | 36.0B | 34.3B | 34.3B | 34.3B | 35.0B |
| Operating Income | 4.47B | 3.45B | 5.11B | 5.91B | 2.18B | 8.54B | 9.10B | 8.20B | 5.89B | 13.7B | 13.6B |
| EBITDA | 6.46B | 6.12B | 6.79B | 7.38B | 4.93B | 20.1B | 19.2B | 19.4B | 3.17B | 15.2B | 16.4B |
| Net Income | 4.46B | 1.01B | 4.92B | 3.44B | -9.02B | 6.99B | 6.33B | 8.03B | -8.95B | 7.05B | 10.9B |
| EPS | 2.65 | 0.61 | 3.01 | 2.01 | -3.99 | 3.12 | 2.95 | 3.86 | -4.41 | 3.46 | 5.30 |
| Balance Sheet | |||||||||||
| Total Assets | 33.7B | 33.6B | 35.0B | 130B | 118B | 109B | 96.8B | 95.2B | 92.6B | 90.0B | 88.8B |
| Total Liabilities | 17.4B | 21.7B | 20.9B | 78.2B | 80.6B | 73.3B | 65.7B | 65.7B | 76.2B | 71.5B | 65.4B |
| Shareholders' Equity | 16.2B | 11.7B | 14.0B | 51.6B | 37.8B | 35.9B | 31.1B | 29.4B | 16.3B | 18.5B | 23.4B |
| Cash & Short-term Investments | 6.35B | 6.81B | 8.76B | 15.4B | 16.5B | 17.2B | 9.25B | 12.3B | 10.9B | 10.7B | 12.6B |
| Total Debt | 6.71B | 7.96B | 7.35B | 47.5B | 51.7B | 45.6B | 40.7B | 41.5B | 51.2B | 47.1B | 44.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.06B | 5.28B | 7.07B | 8.07B | 14.1B | 16.2B | 13.1B | 13.9B | 15.2B | 14.2B | 11.6B |
| Capital Expenditure | 1.22B | 1.06B | 951M | 836M | 753M | 973M | 1.12B | 1.21B | 1.25B | 1.31B | 1.33B |
| Free Cash Flow | 1.84B | 4.22B | 6.12B | 7.23B | 13.3B | 15.2B | 11.9B | 12.7B | 13.9B | 12.8B | 10.2B |
| Ratios | |||||||||||
| ROE | 27.6% | 8.6% | 35.1% | 6.7% | -23.8% | 19.5% | 20.4% | 27.3% | -54.8% | 38.2% | 46.5% |
| ROA | 13.2% | 3.0% | 14.1% | 2.6% | -7.6% | 6.4% | 6.5% | 8.4% | -9.7% | 7.8% | 12.3% |
| Net Profit Margin | 22.9% | 4.8% | 21.8% | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% | 21.7% |
| Debt to Equity | 0.41x | 0.68x | 0.52x | 0.92x | 1.37x | 1.27x | 1.31x | 1.41x | 3.13x | 2.55x | 1.91x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bristol-Myers Squibb Company dividends
- Dividend yield
- 3.89%
- Forward dividend
- 2.52 USD
- Payout ratio
- 71.5%
- Ex-dividend date
- Oct 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.05B | 2.47 | 71.5% |
| 2024 | USD 4.86B | 2.40 | - |
| 2023 | USD 4.74B | 2.28 | 59.1% |
| 2022 | USD 4.63B | 2.16 | 73.2% |
| 2021 | USD 4.40B | 1.96 | 62.9% |
| 2020 | USD 4.08B | 1.80 | - |
| 2019 | USD 2.68B | 1.56 | 77.9% |
| 2018 | USD 2.61B | 1.60 | 53.1% |
| 2017 | USD 2.58B | 1.56 | 255.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1000000:951777 on Aug 7, 2001.
Who owns Bristol-Myers Squibb Company
- Insiders 0.08%
- Institutions 84.88%
- Public & others 15.04%
- Shares outstanding 2.04B
- Free float 2.04B
Top funds holding BMY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 64.8M | 3.17% | -0.09% | Sep 2026 |
| Schwab US Dividend Equity ETF™ | 58.2M | 2.85% | +0.09% | Oct 2026 |
| Vanguard 500 Index Investor | 53.6M | 2.62% | -1.12% | Sep 2026 |
| iShares Core S&P 500 ETF | 27.2M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 26.5M | 1.30% | +0.15% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 24.9M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 19.5M | 0.95% | -0.33% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 14.9M | 0.73% | +0.88% | Oct 2026 |
| Vanguard PRIMECAP Inv | 14.5M | 0.71% | +1.15% | Sep 2026 |
| Vanguard Institutional Index I | 10.8M | 0.53% | -1.02% | Sep 2026 |
| Vanguard High Dividend Yield ETF | 8.31M | 0.41% | +0.27% | Sep 2026 |
| Vanguard Health Care ETF | 6.24M | 0.31% | +0.13% | Sep 2026 |
| Pacer US Cash Cows 100 ETF | 5.90M | 0.29% | +0.13% | Oct 2026 |
| State Street® SPDR® Port S&P 500® ETF | 5.68M | 0.28% | -0.07% | Oct 2026 |
| Columbia Dividend Income Inst | 5.58M | 0.27% | -0.58% | Sep 2026 |
| iShares Core S&P 500 ETF USD Acc | 4.91M | 0.24% | 0.00% | Oct 2026 |
| JPMorgan Equity Premium Income ETF | 4.69M | 0.23% | -0.02% | Oct 2026 |
| Vanguard Health Care Inv | 4.62M | 0.23% | +50.83% | Sep 2026 |
| Schwab® S&P 500 Index | 4.59M | 0.22% | +0.25% | Sep 2026 |
| iShares Russell 1000 Value ETF | 4.49M | 0.22% | +0.02% | Oct 2026 |
Top institutions holding BMY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 180M | 8.82% | +5.07% | Jun 2026 |
| Vanguard Capital Management, LLC | 133M | 6.52% | +0.77% | Jun 2026 |
| State Street Corp | 102M | 5.01% | +3.90% | Jun 2026 |
| JPMorgan Chase & Co | 71.7M | 3.51% | -22.45% | Jun 2026 |
| Charles Schwab Investment Management Inc | 67.6M | 3.31% | +10.60% | Jun 2026 |
| Geode Capital Management, LLC | 56.4M | 2.76% | +2.09% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 46.9M | 2.29% | +1.39% | Jun 2026 |
| NORGES BANK | 36.9M | 1.80% | +2.12% | Jun 2026 |
| Bank of America Corp | 34.0M | 1.67% | +4.48% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 31.7M | 1.55% | +209.34% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 29.0M | 1.42% | -0.65% | Jun 2026 |
| AQR Capital Management LLC | 27.4M | 1.34% | -7.67% | Jun 2026 |
| Ameriprise Financial Inc | 26.7M | 1.30% | +0.75% | Jun 2026 |
| PRIMECAP Management Company | 24.9M | 1.22% | -0.25% | Jun 2026 |
| Northern Trust Corp | 24.9M | 1.22% | +0.64% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 22.8M | 1.12% | +0.53% | Jun 2026 |
| Bank of New York Mellon Corp | 21.8M | 1.07% | -6.35% | Jun 2026 |
| Independent Franchise Partners LLP | 21.8M | 1.07% | +2.43% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 20.0M | 0.98% | +1.80% | Sep 2026 |
| Legal & General Group PLC | 17.0M | 0.83% | +0.86% | Jun 2026 |
Bristol-Myers Squibb Company company profile
- Company name
- Bristol-Myers Squibb Company
- Ticker
- BMY.US
- Exchange
- USA Stocks
- Listed since
- Jan 1, 1972
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 32,500
- Fiscal year end
- December
- Address
- Route 206 & Province Line Road, Princeton, NJ, United States, 08543
- Phone
- 609 252 4621
- Website
- bms.com
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company management
10- Dr. Christopher S. Boerner Ph.D.CEO & Chairman · born 1971
- Mr. David V. ElkinsExecutive VP & CFO · born 1968
- Mr. Greg MeyersExecutive VP and Chief Digital & Technology Officer · born 1973
- Mr. Adam LenkowskyExecutive VP & Chief Commercialization Officer · born 1972
- Mr. Cristian Massacesi M.D.Executive VP, Chief Medical Officer & Head of Development · born 1969
- Ms. Karin ShanahanExecutive VP, Chief Supply Chain & Operations Officer · born 1965
- Mr. Charles E. TrianoSVP & Head of Investor Relations
- Ms. Cari GallmanExecutive VP, General Counsel & Chief Policy Officer · born 1980
- Ms. Ahn Amanda PooleExecutive VP & Chief People Officer · born 1975
- Dr. Joseph J. Eiden Jr.Head of Medical Affairs · born 1949